Paget Disease of Bone

Quick Answer

Paget disease is a focal disorder of excessive, disorganized bone remodeling producing enlarged, weak, hypervascular bone. On bone scintigraphy it is intensely avid with a characteristic "whole-bone" / expanded pattern involving an entire bone or segment — the bone scan is the best tool for mapping polyostotic extent. Alkaline phosphatase tracks activity. A new focus of pain or aggressive lysis raises the rare but critical concern of sarcomatous transformation (which, unlike Paget itself, is FDG-avid).

Definition

Paget disease of bone (osteitis deformans) is a chronic disorder of localized accelerated bone turnover — increased osteoclastic resorption followed by disorganized osteoblastic bone formation — yielding structurally abnormal, enlarged, and fracture-prone bone.

Synonyms

Osteitis deformans; Paget disease of bone. (Distinct from Paget disease of the breast/skin.)

Epidemiology

A disease of older adults, more common in people of European (esp. Anglo-Saxon) descent, with declining incidence in recent decades. Often asymptomatic and discovered incidentally via an elevated alkaline phosphatase or an incidental bone-scan/radiographic finding.

Etiology & Risk Factors

• Genetic: family history; SQSTM1 (p62) mutations (RANK–NF-κB signaling); other loci.
• A paramyxoviral contribution has long been hypothesized but unproven.
• Age.

Pathophysiology

Overactive, abnormal osteoclasts drive resorption, followed by disorganized osteoblastic formation, producing a mosaic pattern of woven and lamellar bone that is enlarged, hypervascular, and mechanically weak. Disease evolves through three phases: lytic (osteoclastic), mixed, and sclerotic (osteoblastic) — reflected in radiographic and scintigraphic appearance.

Genetics & Molecular Biology

SQSTM1/p62 mutations (affecting RANK/NF-κB osteoclast signaling) are the best-established genetic cause, especially in familial disease. The pathway explains the exquisite responsiveness to bisphosphonates (osteoclast inhibitors).

Histopathology

A mosaic pattern of irregular cement lines with woven and lamellar bone, numerous large osteoclasts (with many nuclei), and prominent marrow fibrovascular tissue.

Clinical Presentation

Often asymptomatic. Symptomatic disease causes bone pain, deformity (bowing of long bones, skull enlargement), fractures, secondary osteoarthritis, and — with skull involvement — hearing loss and cranial-nerve effects. Extensive active disease can cause high-output cardiac demand (rare). Sarcomatous transformation (osteosarcoma) is rare but grave.

Laboratory Findings

Elevated alkaline phosphatase (ALP) is the hallmark activity marker (with normal calcium/phosphate in uncomplicated disease); bone-turnover markers (urinary NTX/hydroxyproline) reflect resorption. A disproportionate rise or new symptoms should prompt evaluation for complications.

Imaging Findings by Modality

• Radiographs: cortical thickening, coarse/expanded trabeculae, bone enlargement; "cotton-wool" skull, "blade-of-grass" lytic advancing front in long bones.
• Bone scintigraphy (Tc-99m-MDP): intense "whole-bone" uptake — the best tool for polyostotic mapping of extent.
• NaF-PET: high-resolution alternative for activity/extent.
• CT/MRI: complications (fracture, stenosis, and — key — soft-tissue mass of sarcomatous transformation).
• FDG-PET: uncomplicated Paget is not FDG-avid; FDG avidity flags sarcomatous transformation.

Radiopharmaceutical Uptake Mechanisms

Diphosphonates (MDP) and NaF deposit at sites of intense osteoblastic activity and hypervascularity, explaining the striking uptake in active Paget. FDG is not appreciably taken up by uncomplicated Pagetic bone — so new FDG avidity in a Pagetic bone (with an aggressive lytic/soft-tissue lesion) suggests osteosarcoma.

Typical PET / SPECT Tracers

Therapy Indications

• Bisphosphonates — potent osteoclast inhibitors; zoledronic acid gives durable biochemical remission; treat for symptoms, active disease near joints/weight-bearing bone, planned surgery, or hypercalcemia.
• Analgesia and orthopedic management of deformity/fracture.
• Monitor response by ALP and symptoms.

Theranostics

None — the nuclear-medicine role is diagnosis, extent mapping, activity, and detecting complications (especially sarcomatous transformation).

Differential Diagnosis

• Blastic metastases (e.g. prostate/breast) — but Paget's bone enlargement/expansion and whole-bone pattern differ.
• Fibrous dysplasia (younger, ground-glass), osteosarcoma (aggressive lysis + soft-tissue mass — transformation), and other metabolic bone disease.

Reporting Checklist

• Describe the whole-bone / expanded avid pattern and polyostotic extent.
• State disease phase and activity if evident; correlate with ALP.
• Explicitly flag features of sarcomatous transformation (new aggressive lysis, soft-tissue mass, new FDG avidity, disproportionate pain).

Prognosis

Uncomplicated Paget is benign and well controlled by bisphosphonates. Morbidity comes from deformity, fracture, arthritis, and hearing loss; the rare osteosarcoma transformation carries a poor prognosis — hence the importance of recognizing warning features.

Board Pearls

On bone scintigraphy, Paget shows intense "whole-bone" / expanded uptake involving an entire bone or segment — the bone scan is the best tool for mapping polyostotic extent. Alkaline phosphatase is the activity marker, and bisphosphonates (zoledronic acid) are the treatment.

Uncomplicated Paget is not FDG-avid — new FDG avidity (with aggressive lysis, a soft-tissue mass, or disproportionate new pain) flags the rare but grave sarcomatous (osteosarcoma) transformation.

Radiographic signatures — "cotton-wool" skull and the "blade-of-grass" lytic front — reflect the three phases (lytic → mixed → sclerotic). Distinguish Paget from blastic metastases by its bone enlargement/expansion and whole-bone pattern, and from fibrous dysplasia by age/appearance.

Related Pages

• Tracers: MDP/HDP bone agents, NaF bone PET; related: bone scintigraphy.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A three-phase Paget schematic (lytic → mixed → sclerotic) with radiographic/scintigraphic correlates.
• A "whole-bone" bone-scan teaching image (expanded avid segment).
• A transformation-warning panel (new lysis + soft-tissue mass + FDG avidity).

Common Pitfalls

• Extensive polyostotic Paget can be mistaken for widespread skeletal metastases (and can mask coexisting metastases) — the whole-bone involvement, bone expansion, and cortical thickening distinguish it from discrete metastatic foci.
• Sarcomatous transformation may appear as a relatively photopenic or heterogeneous focus within otherwise intensely avid Pagetic bone on the bone scan — uniform hot uptake does not exclude malignancy; look for new lysis, a soft-tissue mass, and FDG avidity.
• The lytic "blade-of-grass" advancing front and "cotton-wool" skull sclerosis can be misread as aggressive lytic or blastic metastasis on radiographs/CT.
• After bisphosphonate therapy, scintigraphic uptake and ALP fall — read a quieter follow-up scan as treated disease, not as a separate resolving process.

Self-Check (Board-Style)